Apogee reports Q1 loss of $74.1M; $1.3B cash; zumilokibart Phase 3 AD on track

Apogee Therapeutics, Inc.

2026-Q1 EPS reported -$1.06

Net loss of $74.1M in Q1 2026 vs. $55.3M a year ago; R&D spend $60.8M, G&A $22.0M.
Cash, equivalents and securities total $1.3B, up from $902.9M at Dec 2025, aided by $403M equity offering; runway into 2029.
APEX Part A 52-week data: 75% (3-month) and 85% (6-month) of EASI-75 responders maintained; IGA 0/1 maintained at 86% and 78%.
APEX Part B 16-week data in AD expected Q2 2026; Phase 3 AD initiation planned H2 2026.
Positive Phase 1b asthma data shared Jan 2026; asthma and EoE trial details expected later this year.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Apogee Therapeutics, Inc. reported financial results for the quarter ended March 31, 2026.

Period: the quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 11, 2026, Apogee Therapeutics, Inc. (the “Company”) issued a press release providing a business update and announcing its financial results for the quarter ended March 31, 2026 (the “Earnings Press Release”).

View on SEC.gov

Browse all earnings releases →

Apogee Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-215683

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.